Oruka Therapeutics is focused on improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. Self-described as committed to advancing potentially best-in-class monoclonal antibodies for treatment.

Oruka Therapeutics

Oruka Therapeutics | 2,597 followers on LinkedIn. A new era for chronic skin diseases | Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions

Biopharmaceutical Quality Operations Management

Katherine Guise, CQA

VP, Medical Affairs at Oruka Therapeutics

Eugenia Levi

Sr. Director, Clinical Data Management

Evelyn Dorsey

Vice President Regulatory Affairs at Oruka Therapeutics

Jodi Parsons

October 29 is #WorldPsoriasisDay . This year’s theme of “Family” highlights the impact of psoriatic disease on over 100 million people worldwide as well as their loved ones. Psoriasis presents unique challenges not only for those affected but also for their families. At Oruka, we’re dedicated to developing new treatments that aim to ease this burden by offering those living with psoriasis the greatest possible freedom from disease.

We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.

We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.

We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.

ORUK

COM:ORUKATX

Oruka Therapeutics